Phase I Randomized, Double-blind, Placebo-controlled, Single Multiple Dosing, Dose Escalation, and Food Effect Study of GS3-007A Oral Liquid in Chinese Healthy Adults
Latest Information Update: 07 Sep 2023
At a glance
- Drugs GS3-007 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors GeneScience Pharmaceuticals
- 10 Apr 2023 Status changed from recruiting to completed.
- 15 Nov 2022 New trial record